Polatuzumab Vedotin Combined with Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) for Patients with Previously Untreated Diffuse Large B-Cell Lymphoma (DLBCL): Preliminary Results of a Phase Ib Dose-Escalation - Université de Rennes Access content directly
Journal Articles Blood Year : 2015

Polatuzumab Vedotin Combined with Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) for Patients with Previously Untreated Diffuse Large B-Cell Lymphoma (DLBCL): Preliminary Results of a Phase Ib Dose-Escalation

Abstract

Conference: 57th Annual Meeting of the American-Society-of-Hematology - Orlando, FL - DEC 05-08, 2015
No file

Dates and versions

hal-01290426 , version 1 (18-03-2016)

Identifiers

  • HAL Id : hal-01290426 , version 1

Cite

Nancy L. Bartlett, Andy I. Chen, Kathryn S. Kolibaba, Thierry Lamy, Surai Jones, et al.. Polatuzumab Vedotin Combined with Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) for Patients with Previously Untreated Diffuse Large B-Cell Lymphoma (DLBCL): Preliminary Results of a Phase Ib Dose-Escalation. Blood, 2015, 126 (23), pp.2726. ⟨hal-01290426⟩
44 View
0 Download

Share

Gmail Facebook X LinkedIn More